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Objectives. We sought o determine the incidence and indepen- 
dent prognostic value of increased serum levels of sensitive 
serologic markers in patients in whom a conventionally diagnosed 
acute myocardial infarction had been ruled out. 
Background. Increased serum levels of creatine kinase (CK) 
isoenzyme MB mass and cardiac troponin T in patients with 
unstable angina pectoris are associated with a poor prognosis. 
Methods. We analyzed ata from 196 consecutive patients with 
suspected acute myocardial infarction, which was later ruled out 
in 124. Increased serum levels of CK-MB mass, troponin T and 
myosin light chains were compared with clinical findings, ST-T 
wave abnormalities and presence of arrhythmias. 
Results. Of the patients in the noninfarction group, 28% had 
serum CK-MB mass >6 pg/liter, 20% had troponin T >0.20 pg/liter, 
and 26% had myosin light chains >0.4 #g/liter (discrimination 
limits). The cardiac event rate (cardiac death, nonfatal acute myo- 
cardial infarction) within 28 months was significantly higher in 
patients in the noninfarction group with elevated marker levels 
(range 22% to 24%) than in patients with values below these 
discriminators (range 3% to 5%) but was not significantly different 
from that in patients with a definite diagnosis of acute myocardial 
infarction (29%). Further, significant predictors of cardiac events 
were previous myocardial infarction; myocardial infarction or angina 
pectoris, or both; previous congestive heart failure; ST-T wave 
abnormalities on admission; a transient ST-T wave shift on serial 
electrocardiograms (ECGs); recurrent chest pain; and occurrence of 
supraventricular or ventricular tachycardia, or both, during the 1st 
48 h after admission. It was found that all three biochemical 
markers, in the main, convey independent prognostic information 
with respect to dinical findings and presence of arrhythmias but not 
ST-T wave abnormalities on admission or a transient ST-T wave shift 
on serial ECGs. 
Conclusions. Increased serum levels of CK-MB mass, troponin 
T and myosin light chains all detect a subgroup of 25% of patients 
without acute myocardial infarction who have as poor a prognosis 
as that of patients with a definite diagnosis of acute myocardial 
infarction. All three biochemical markers provide similar impor- 
tant independent prognostic information with regard to clinical 
findings and arrhythmias but add no additional prognostic infor- 
mation once ECG ST-T wave changes are considered. 
(JAm Coil Cardiol 1995;25:574-81) 
The diagnosis of acute myocardial infarction is based on typical 
clinical history, electrocardiographic (ECG) changes and char- 
acteristic serial changes in plasma enzyme levels (1,2), in 
particular serum creatine kinase (CK) isoenzymes and lactate 
dehydrogenase isoenzyme (1). However, in the late mid-1980s 
improved immunoassays were developed to measure the mass 
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concentration of serum CK-MB rather than its catalytic activ- 
ity, as well as new immunoassays to measure structural pro- 
teins of the heart (troponin T, troponin I and myosin light 
chains) (3-10). Serum CK-MB mass and troponin T have been 
the subject of particular investigation. These assays have 
proved useful not only in the conventional diagnosis of acute 
myocardial infarction, but also in the diagnosis of minor 
myocardial injury among patients in whom an acute myocar- 
dial infarction has been ruled out (3,4,11-15). It has been 
shown (3,12-15) that in 26% to 35% of such patients, the 
prognosis is similar to that in patients with a definite diagnosis 
of acute myocardial infarction. However, to our knowledge no 
study to date has investigated whether increased serum levels 
of CK-MB mass, troponin T and myosin light chains are of 
independent prognostic value. We therefore attempted to 
determine whether increased serum levels of these biochemi- 
cal markers add independent prognostic information to clinical 
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findings, ST-T wave abnormalities and arrhythmias in patients 
with suspected acute myocardial infarction and to evaluate 
whether troponin T and myosin light chains are superior to or 
complement CK-MB mass in this respect. 
Methods  
Patients. Two hundred thirty-five patients with suspected 
acute myocardial infarction who were admitted consecutively 
to the coronary care unit were considered for inclusion in the 
study. Patients were not included if they had undergone 
resuscitation (  = 6), had a documented myocardial infarction 
within the previous fortnight (n = 1), were residing in another 
county (n = 3) or had fewer than two blood samples drawn 
(n = 16). 
In the coronary care unit, routine diagnostic procedures 
were based on history, medical examination, serial standard 
12-lead ECG and laboratory tests described later. Patients 
were classified as those with and without acute myocardial 
infarction on the basis of a diagnosis made within 48 h of 
admission. 
Patients with acute myocardial infarction. Seventy-two 
patients had a definite acute myocardial infarction according to 
World Health Organization criteria (2): 1) typical chest pain; 
2) unequivocal ECG changes, that is, a new pathologic Q wave 
or evolution of a current injury (ST segment elevation lasting 
>24 h, followed by T wave inversion); and 3) characteristic 
increase in serum enzyme levels. For this study we used the 
following discrimination limits: serum CK >200 U/liter in men 
or 150 U/liter in women; serum CK-MB activity >24 U/liter 
and serum lactate dehydrogenase isoenzyme 1 >170 U/liter 
(blood sampling procedures and analytic methods are de- 
scribed later) (16,17). 
Patients without acute myocardial infarction. In 137 pa- 
tients who did not meet the previous criteria, acute myocardial 
infarction was ruled out. Reasons for admission were chest 
pain (n = 117), pulmonary edema (n = 9), tachyarrhythmias 
(n = 6) and fainting (n = 5). Of the 117 patients with chest 
pain, 72 (62%) had unstable angina that could be categorized 
according to the Braunwald (18) classification of unstable 
angina: class 1 = severe or accelerated angina of new onset 
(n = 2); class 2 = subacute angina at rest (i.e., not active within 
the previous 48 h) (n = 0); and class 3 = angina at rest within 
the previous 48 h (n = 70). Of the remaining 45 patients, 21 
performed a bicycle exercise test with no sign of ischemia (the 
bicycle exercise test was carried out until exhaustion; no 
patient developed chest pain; median maximal work load was 
160 W, range 90 to 240; no signs of isehemia ppeared on the 
ECG [i.e., ->0.1-mV ST segment depression 0.08 s after the J 
point]), and an exercise test was inconclusive or could not be 
carried out because of administrative or physical reasons in 11 
patients. An obvious nonischemic etiology of chest pain was 
established in the remaining 13 patients, who were omitted 
from further analysis: pericarditis or endocarditis (n = 4), 
pneumonia (n = 2), pulmonary cancer (n = 1), cholecystitis 
(n = 1), gastritis (n = 1), hyperventilation (  = 1), thyreotoxi- 
cosis (n = 1), Marfan syndrome (n = 1) and fibromyalgia (n = 1). 
Thus, the study included 72 patients with and 124 without 
acute myocardial infarction. Patients readmitted uring the 
follow-up period were included on their first admission only. 
Electrocardiography, Electrocardiography was performed 
on admission and thereafter at least once daily for all pa- 
tients. The following definitions were used: ST-T wave abnor- 
malities = ST segment deviation (ST segment depression 
->0.1 mV or elevation ->0.1 mV in limb leads or 0.2 mV in 
precordial leads) or Y wave inversion, or both, on the ECG; 
uncodable ECG = poor quality or the presence of suppression 
codes (i.e., bundle branch block, artificial pacemaker, complete 
atrioventricular block). We further classified the patients ac- 
cording to the daily ECG recordings as those having a transient 
ST-T wave shift or no or nonprogressive ST-T wave abnormal- 
ities. 
The ECGs were evaluated independently by two of the 
investigators (J.R., H.N.) who had no knowledge of the 
biochemical marker esults. A consensus was reached in cases 
of discrepancy. 
Blood sampling. Blood sampling was performed according 
to a programmed time schedule (19). Blood samples were 
collected three times daily (8 AM and 2 and 8 PM) for up to 48 h. 
The first sample was drawn at the first of these fixed times after 
admission. The samples were drawn into tubes without an 
anticoagulant agent. After coagulation, the samples were cen- 
trifuged at 3,000 g for 10 rain. The serum was stored at a 
minimal temperature of -80°C until analysis. After thawing, 
the serum was again centrifuged to remove any precipitate. 
The serum levels of CK and CK-MB activity were determined 
for all samples; lactate dehydrogenase i oenzyme i levels were 
determined for samples drawn at 8 AM. In the present study, 
serum levels of CK-MB mass, troponin T and myosin light 
chains were determined for all samples. 
Analytic methods. Serum CK-MB mass concentrations 
were determined by an immunoenzymetric assay (NovoClone, 
DAKO, Denmark), which is based on a two-site immunometric 
sandwich method using two monoclonal antibodies (details 
have been reported elsewhere [9]). The detection limit for 
CK-MB was 0.1 /xg/liter, and the intraassay coefficient of 
variation was 0.03 at a reference value of -6/xg/liter (9). The 
analysis used two different discriminator values based on the 
results of previous tudies (8 and 6/~g/liter) (4,9,13,14). 
Troponin T immunoassay [ELISA Troponin(e) T] was car- 
ried out using the Enzymun-Test System ES22 analyzer 
(Boehringer Mannheim GmbH, Mannheim, Germany), which 
is based on a single-step sandwich principle (20), with 
streptavidin-coated ubes as the solid phase and two monoclo- 
nal antihuman cardiac troponin T antibodies (measuring range 
0.00 to 15/zg/liter) (4,20). The intraassay coefficient of varia- 
tion was 0.06 at -0.20 /zg/liter (15), and the discriminator 
value used was 0.20 gg/liter (4,12,15). 
Human ventricular myosin light chain isotype 1 levels were 
measured by a newly developed immunoenzymetric assay 
(Novo-Nordisk Bioscience A/S, Copenhagen, Denmark) and is 
based on a two-site immunometric sandwich method with two 
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monoclonal antibodies (7). The detection limit for myosin light 
chains is 0.4/zg/liter, which was also used as the discrimination 
limit because reference subjects do not have detectable 
amounts of myosin light chains in serum (99% percentile in 
190 reference subjects) (7). The intraassay coefficient of vari- 
ation was 0.13 at -1  tzg/liter. 
Catalytic activity levels of serum CK, CK-B and lactate 
dehydrogenase isoenzyme 1 were determined at 37°C on a 
Cobas Bio (Hoffmann-La Roche, Basel, Switzerland). Serum 
CK levels were determined by the method of the Committee 
on Enzymes of the Scandinavian Society for Clinical Chemistry 
and Clinical Physiology (reference range in normal subjects 
-<200 U/liter in men, -<150 U/liter in women) (16,21), and 
serum CK-B activity was determined after immunoinhibition 
of the M subunit, both using reagents from Boehringer Mann- 
helm. The CK-B results were multiplied by 2 to be expressed as 
serum CK-MB (discriminator value -<24 U/liter) (16,17). Be- 
cause the reference range for CK-MB activity is <12 U/liter, 
we also analyzed the data using 18 and 12 U/liter as discrimi- 
nator values (17). Serum lactate dehydrogenase isoenzyme 1
levels were determined using the immunoprecipitation method 
(Hoffmann-La Roche) (discriminator value -<170 U/liter) (19). 
Follow-up. The patients were followed up for 28 months 
after admission to record cardiac events (nonfatal acute myo- 
cardial infarction or cardiac death [fatal acute myocardial 
infarction, sudden cardiac death or other cardiac death]). 
Information was obtained from the hospital records of the 
local county central registry, which contains complete informa- 
tion on all hospital admissions in the county. Admission to 
hospital for suspected acute myocardial infarction is routine. 
No patients were lost to follow-up. At the end of the study, 39 
of the 196 patients had died (cardiac deaths, n = 29; noncar- 
diac deaths, n = 10). Death certificates were available for all 
patients and autopsy reports for 15 (38%) of 39. A total of 382 
patient-years atrisk had been accumulated (mean 2.0, range 3 
days to 2.3 years). 
Statistics. Between-group comparisons were performed 
using the Fisher exact est. The Mann-Whitney U test was used 
for comparisons of age. The Kaplan-Meier method and a 
log-rank test were used for univariate analysis of time to 
cardiac events (see earlier). Noncardiac death was treated as a 
censored observation. Exact logistic regression analysis was 
used to estimate the independent prognostic value of biochem- 
ical markers compared with clinical and ECG findings in 
bivariate statistical analysis. All tests were computerized using 
Bio Medical Data Packing statistical software and Statistical 
Software for Exact Nonparametric Inference (22,23); p = 0.05 
was considered significant. 
Resu l ts  
Medical history and clinical outcome. More patients with 
acute myocardial infarction ruled out had a history of angina 
pectoris (p = 0.02), previous myocardial infarction (p = 0.03), 
coronary angiography (p = 0.008) and coronary artery bypass 
graft surgery or percutancous transluminal coronary anglo- 
Table 1. Demographic Data 
Patients 
Patients With AMI 
With AMI Ruled Out 
(n - 72) (n = 124) 
Gender 
Male 47 (65%) 78 (63%) 
Female 25 (35%) 46 (37%) 
Age (yr) 
Mean _+ SD 67 + 12 63 _+ 11 
Range 36-89 38-87 
Medical history 
Angina pectoris 18 (25%) 52 (42%) 
Previous AMI 13 (18%) 41 (33%) 
CABG/PTCA 1 (1%) 19 (15%) 
Coronary angiography 3 (4%) 22 (18%) 
Congestive h art failure 10 (14%) 22 (18%) 
Hypertension* 8 (11%) 10 (8%) 
Hypercholesterolemia? 39 (54%) 62 (50%) 
Diabetes mellitus 8 (11%) 9 (7%) 
Smoker~ 36 (50%) 66 (58%) 
Follow-up 
Cardiac events§ 21 (29%) 11 (9%) 
Nonfatal AMIs 9 5 
Later cardiac deaths 6 4 
Cardiac deaths 12 6 
CABG 2 (3%) 3 (2%) 
PTCA 4 (6%) 5 (4%) 
*Diastolic blood pressure >95 mm Hg or medical therapy for hypertension, 
or both. ?Total cholesterol >6 mmol/liter or medical therapy for hypercholes- 
terolemia, or both. :~Smoker on admission; status unknown in 11 patients. 
§Nonfatal or fatal acute myocardial infarction (AMI), sudden or other cardiac 
death. Data presented are number (%) of patients, unless otherwise indicated. 
CABG - coronary artery bypass graft surgery; PTCA - percutaneous translu- 
minal coronary angioplasty. 
plasty (p = 0.002) than patients with acute myocardial infarc- 
tion. Patients with acute myocardial infarction were somewhat 
older than those without acute myocardial infarction (p = 
0.007); otherwise, the groups were similar (Table 1). 
The follow-up period included hospital stay and the period 
after discharge. In hospital, the mortality rate was 11% (8 of 
72) in patients with acute myocardial infarction and 1.6% (2 of 
124) in patients without acute myocardial infarction. The 
percent of patients with cardiac events was higher in those with 
than without acute myocardial infarction (log-rank test, p = 
0.0001) (Table 1, Fig. 1) and was 25% and 6% after 1 year, 
respectively. Coronary artery bypass graft surgery or percuta- 
neous transluminal coronary angioplasty was later performed 
in 8% of patients with and 6% of patients without acute 
myocardial infarction. None of the patients without acute 
myocardial infarction who had a later cardiac event underwent 
either of these procedures during the follow-up period. 
Biochemical subgrouping of patients without acute myocar- 
dial infarction. Maximal values from the serial sampling per- 
formed within 48 h after admission in patients with and without 
acute myocardial infarction and those without acute myocar- 
dial infarction subgrouped according to serum CK-MB mass 
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Figure 1. Top, Cl inical outcome of pat ients with and without acute 
myocardial infarction (AMI) (log-rank test, p = 0.0001). End points 
were cardiac death or nonfatal acute myocardial infarction. Numbers 
below abscissa indicate patients at risk during follow-up. Bottom, 
Clinical outcome after patients without acute myocardial infarction 
were assigned to two subgroups on the basis of serum creatine kinase 
(CK) MB isoenzyme mass, troponin T and myosin light chain levels. 
End points were cardiac death or nonfatal acute myocardial infarction. 
A = patients with acute myocardial infarction (similar to those in the 
top panel); B = serum troponin T ->0.20/~g/liter; C = serum myosin 
light chains ->0.4/~g/liter; D = serum CK-MB mass >-6/zg/liter; E = 
serum troponin T <0.20 /zg/liter; F = serum myosin light chains 
<0.4/zg/liter; G = serum CK-MB mass <6/zg/liter. p = 0.52, acute 
myocardial infarction versus erum CK-MB mass >-6/~g/liter, log-rank 
test. p = 0.63, acute myocardial infarction versus serum troponin T 
->0.20 p.g/liter, log-rank test. p = 0.49, acute myocardial infarction 
versus erum myosin light chains >-0.4/~g/liter, log-rank test. 
->6/~g/liter, troponin T ->0.20 ~g/liter and myosin light chains 
->0.4 p~g/liter are presented in Table 2. Of the patients without 
acute myocardial infarction, all three markers were below their 
respective discrimination limits in 59%; one marker was ele- 
vated in 20%, two markers in 9%, and all three markers in 
12%. 
There was no difference in medical treatment (nitroglycer- 
in, beta-adrenergic blocking agents, calcium channel blocking 
agents, angiotensin-converting enzyme inhibitors, acetylsali- 
cylic acid or other anticoagulant agents) between the sub- 
groups of patients without acute myocardial infarction who 
had increased versus decreased serum troponin T values or 
increased versus decreased myosin light chain values on ad- 
mission or at discharge. Patients with increased serum CK-MB 
mass concentration had similar results, but more patients with 
decreased CK-MB mass values were discharged with calcium- 
blocker therapy. 
Among the eight patients without acute myocardial infarc- 
tion who underwent coronary artery bypass graft surgery or 
percutaneous transluminal coronary angioplasty during the 
follow-up period, one had elevated serum CK-MB mass, 
troponin T and myosin light chain levels, one had elevated 
serum troponin T, and two had elevated serum myosin light 
chain levels. 
Univariate analysis for patients without acute myocardial 
infarction (log-rank test). Patients without acute myocardial 
infarction were subgrouped according to clinical findings, ST-T 
wave abnormalities on admission, a transient ST-T wave shift 
and presence of arrhythmias and biochemical marker levels 
during the 1st 48 h after admission (Table 3). Data for patients 
who had a cardiac event are displayed in Table 4. 
Independent prognostic value for patients without acute 
myocardial infarction (exact logistic regression analysis). 
Serum CK-MB mass ->6 /zg/liter, troponin T ->0.20 /~g/liter 
and myosin light chains ->0.4 ~g/liter add, in the main, 
independent prognostic information with regard to all clinical 
findings and arrhythmias found significant in the univariate 
analyses but not ST-T wave abnormalities on admission or a 
transient ST-T wave shift in serial ECGs (Table 5). Estimated 
odds ratios between cardiac events and clinical or ECG 
findings, adjusted for biochemical marker serum levels, were 
calculated in a manner similar to those in Table 5. Knowledge 
of previous myocardial infarction; myocardial infarction or 
angina pectoris, or both, showed independent prognostic in- 
formation with respect to biochemical markers but not for 
other clinical findings, ST-T wave abnormalities on admission, 
a transient ST-T wave shift in serial ECGs or arrhythmias. 
Discuss ion  
The key question is whether increased serum levels of 
CK-MB mass, troponin T and myosin light chains are of 
independent prognostic value in patients in whom an acute 
myocardial infarction is ruled out. We studied these variables 
in all patients with a suspected acute myocardial infarction who 
were admitted to the coronary care unit, including those with 
a definite diagnosis of acute myocardial infarction who were 
included in the study as a reference group for prognosis. We 
found a 1-year cardiac event rate of 25% for patients with and 
6% for those without acute myocardial infarction (p = 0.0001), 
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Table 2, Maximal Values of Biochemical Markers in Serum Within 48 h After Admission 
Patients With AMI Patients With AMI Ruled Out 
(n - 72) (n = 124) 
CK (U/liter) 752 (51-4,600) 89 (24-733) 
CK-MB activity (U/liter) 88 (8-1,012) 8 (0-134) 
CK-MB mass (~g/liter) 122 (3.6-712) 3.7 (0.7-22.8) 
LD 1 (U/liter)* 442 (131-2,600) 94 (37-327) 
Troponin T (ttg/liter) 4.49 (0.67-39.4) 0.02 (0.00-2.06) 
Myosin light chains (~g/liter) 12.5 (1.0-97.2) 0.0 (0.0-11.5) 
Patients With AMI Ruled Out 
CK-MB Mass <6/xgjliter CK-MB Mass ->6 ttg/liter 
(n - 89) (n = 35) 
CK (U/liter) 74 (24-733) 124 (41-458) 
CK-MB activity (U/liter) 8 (0-134) 10 (4-22) 
CK-MB mass (,ag/liter) 2.9 (0.7-5.9) 9.9 (6.1-22.8) 
Troponin T (p@qiter) 0.00 (0.00-1.20) 0.19 (0.00-2.06) 
Myosin light chains (~g/liter) 0.0 (0.0-5.6) 1.1 (0.0-11.5) 
Troponin T <0.20 tzg/liter Troponin T >0.20 gg/liter 
(n 99) (n - 25) 
CK (U/liter) 84 (24-733) 104 (49-458) 
CK-MB activity (U/liter) 8 (0-134) 12 (4-20) 
CK-MB mass (~g:'liter) 3.4 (0.7-21.5) 7.3 (2.5-22.8) 
Yroponin T (p.g]liter) 70.0 (0.00 0.19) 0.35 (0.20-2.06) 
Myosin light chains (gg/liter) 0.0 (0.0-5.6) 1.4 (0.0-11.5) 
Myosin Light Chains <0.4 p.g/liter Myosin Light Chains ->0.4 ixg/liter 
(n - 92) (n - 32) 
CK (U/liter) 79 (24-429) 128 (49-733) 
CK-MB activity (U/liter) 8 (0-134) 12 (4-22) 
CK-MB mass (rig/liter) 3.4 (0.7-21.5) 8.0 (2.3-22.8) 
Yroponin T (/xg/liter) 0.0 (0.00-1.20) 0.24 (0.00-2.06) 
Myosin light chains (ttg/liter) 0.0 (0.0-<0.4) 1.6 (0.4-11.5) 
*Value unknown in five patients. Data presented are median value (range). AMI acute myocardial infarction; 
CK = creatine kinase; LD 1 = lactate dehydrogenase isoenzyme 1. 
similar to previous observations (13,24-26). A history of 
angina pectoris or previous myocardial infarction as well as a 
slightly younger age were more frequent among patients 
without than with acute myocardial infarction. Thus, our 
findings in patients without acute myocardial infarction corre- 
spond well to those of other studies (15,26). 
Biochemical subgrouping and clinical outcome. Patients 
without acute myocardial infarction were subgrouped accord- 
ing to various discriminator values chosen from previous 
studies of CK-MB mass, troponin T and myosin light chains 
(4,9,12-15). Those patients without acute myocardial infarc- 
tion who had maximal serum CK-MB mass ->6 /tg/liter, 
troponin T ->0.20 ~g/liter or myosin light chains ->0.4/xg/liter 
had a cardiac event risk rate of 22% to 24%, significantly 
higher than the 3% to 5% rate in patients with values below the 
discrimination limits but not different from risk rates in 
patients with acute myocardial infarction (Fig. 1, bottom). 
However, neither unspecific elevation of CK levels nor fluctu- 
ations of CK levels within the normal reference range nor 
CK-MB activity with even lower discrimination limits offers 
prognostic information with respect o patients without acute 
myocardial infarction. A poor signal-to-noise ratio, when lower 
discriminatory values of CK-MB activity measured by immu- 
noinhibition are used, is probably why CK-MB activity is not 
able to detect patients with a poor prognosis. Thus, conven- 
tional enzyme levels are inferior to the new sensitive biochem- 
ical markers for detecting patients without acute myocardial 
infarction who have a poor prognosis. Because most patients 
without acute myocardial infarction who had CK-MB mass, 
troponin T, and myosin light chains values that were all either 
above or below the discrimination limits used, each of these 
biochemical markers is equally viable for use in prognosis. 
Beyond this, the choice of marker depends on the additional 
information required and local laboratory facilities (3-7). 
Predictors of clinical outcome. In accordance with other 
investigators (26,27), the clinical and ECG variables found 
significant for a poor prognosis were previous myocardial 
infarction; myocardial infarction or angina pectoris, or both; 
previous congestive heart failure; ST-T wave abnormalities on 
admission; a transient ST-T wave shift on serial ECGs; recur- 
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Table 3. Univariate Analysis of Risk Factors for Cardiac Events in Patients in Whom Acute Myocardial Infarction Is Ruled Out Over a 
28-Month Follow-Up 
Relative 
No. of Patients p Value Frequency of 
(no. of cardiac events*) (log-rank) Cardiac Events* 
Total 
M/F 
Age (yr) -<60/>60 
Before admission 
Angina pectoris No/Yes 
MI No/Yes 
MI/angina pectoris No/yes 
Congestive heart failure No/Yes 
Hypertension1 No/Yes 
Hypercholesterolemia$ No.Yes 
Diabetes mellitus No/Yes 
Smoker§ No/yes 
Admission ECG 
Sinus tachycardia (>100 beats/min) No/Yes 
ST-T wave abnormalities (23 uncodable) No/yes 
During admission, 1st 48 h 
Repeated chest pain No/Yes 
ECG 
Sinus tachycardia (> 100 beats/min) No/Yes 
Transient ST-T wave shift (20 uncodable) No/yes 
Sinus rhythm/SVT and/or VT (8 uncodable) 
BBB, complete AV block (10 uncodable) No/yes 
Biochemical markers 
CK-MB mass <8/>8 ~tg/liter 
CK-MB mass <6/->6 ,ag/liter 
Troponin T <0.20/->0.20 ,ttgJliter 
Myosin light chains <0.4/>0.4 ,agjliter 
CK (M 200 U/liter; F 150 U/liter) -<200; <150/'>200; >150 
CK (M 200 U/liter; F 150 U/liter) -<200; <-150 and no 
variationll/>200; >150 or -<200; -<150 and variationll 
CK-MB activity -<24/>24 U/liter 
CK-MB activity <18/_>18 U/liter 
CK-MB activity <12/_>12 U/liter 
124(11) 
78/46 (6/5) 0.52 7.7%/10.9% 
50/74 (2/9) 0.10 4.0%/12.2% 
72/52 (4/7) 0.12 5.6%/13.5% 
83/41 (3/8) 0.002 3.6%/19.5% 
61/63 (1/10) 0.004 1.6%/15.9% 
102/22 (6/5) 0.005 5.8%/22.7% 
114/10 (9/2) 0.19 7.9%/20.0% 
62/62 (4/7) 0.35 6.5%/11.3% 
115/9 (11/0) 0.33 9.6%/0% 
47/66 (4/4) 0.85 8.5%/6.1% 
105/19 (11/0) 0.16 10.5%/0% 
63/38 (1/7) 0.002 1.5%/18.4% 
104/20 (7/4) 0.047 6.7%/20.0% 
111/13 (11/0) 0.27 9.9%/0% 
80/24 (4/5) 0.01 5.0%/20.8% 
86/30 (5/6) 0.02 5.8%/20.0% 
99/15 (8/2) 0.46 8.0%/13.3% 
100/24 (7/4) 0.09 7.0%/16.7% 
89/35 (3/8) 0.0003 3.4%/22.9% 
99/25 (5/6) 0.002 5.1%/24.0% 
92/32 (4/'7) 0.001 4.3%/21.9% 
112/12 (10/1) 0.95 8.9%/8.3% 
66/58 (7/4) 0.45 10.6%/6.9% 
119/5 (11/0) 0.48 9.2%/0% 
112,/12 (9/2) 0.26 8.0%/16.7% 
88/36 (7/4) 0.47 8.0%/11.1% 
*Nonfatal or fatal acute myocardial infarction (MI), sudden or other cardiac death, tDiastolic blood pressure >95 mm Hg or medical treatment for hypertension, 
or both. STotal cholesterol >6 mmol/liter or medical treatment for hypercholesterolemia, or both. §At admission, status unknown in 11 patients. 1180% difference 
between the lowest and highest value below the discrimination limit. AV = atrioventricular; BBB - bundle branch block; CK = creatine kinase; ECG = 
electrocardiogram; F female; M male; SVT - supraventricular tachycardia; VT - vcntricular tachycardia. 
Table 4. Maximal Values of Serum Biochemical Markers in Patients With a Cardiac Event After Acute Myocardial Infarction Had Been 
Ruled Out 
ECG ST-T Myosin 
Reason Wave Transient CK-MB CK-MB Light 
Pt Gender/ for Abnormalities ST-T CK Activity Mass LD 1 Troponin T Chains 
No. Age (yr) Admission on Admission Wave Shift (U/liter) (U/liter) 0xg/liter) (U/liter) (tzg/liter) (t~g/liter) 
Cardiac 
Event, 
Days After 
Admission 
1 M/55 UAP3 Yes No 92 8 3.5 84 0.02 0.0 Death, 379 
2 F/75 UAP3 Uncodable No 69 8 6.3 96 0.00 0.0 AMI, 621 
3 M/66 PE Uncodable Uncodable 173 18 14.5 347 0.39 16.4 Death, 8 
4 M/76 UAP3 Yes Yes 143 12 18.8 111 0.98 0.4 Death, 66 
5 M/81 UAPI Yes Yes 49 4 2.6 103 0.28 0.5 AMI, 284 
6 F/67 UAP3 No No 266 18 9.5 201 0.32 2.7 Death, 4 
7 F/73 UAP3 Uncodable Uncodable 70 8 11.8 134 0.14 0.3 Death, 199 
8 F/53 UAP3 Yes Yes 139 12 7.8 56 0.00 1.1 AMI, 9 
9 M/70 PE Yes No 75 8 2.8 253 0.02 0.0 Death, 749 
10 F/73 UAP3 Yes Yes 56 8 6.4 88 0.22 1.4 AMI, 15 
11 M/83 UAP3 Yes Yes 124 10 6.4 101 0.20 1.3 AMI, 841 
PE - pulmonary edema: Pt = patient; UAP = unstable angina pectoris (Braunwald classification 1,3); other abbreviations a  in Tables 2 and 3. 
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Table 5. Estimated Odds Ratios for Cardiac Events and Serum Biochemical Markers Adjusted for Clinical or Electrocardiographic Findings 
in Patients With Acute Myocardial Infarction Ruled Out 
Clinical Findings ECG Findings 
ST-T Wave Transient 
Previous Previous Previous Recurrent Abnormalities ST-T Wave 
Age >60 yr MI MI/Angina CHF Chest Pain* on Admission Shift Arrhythmias? 
CK-MB mass 7.1 + 7.8+ 8.8+ 6.6§ 7.9+ 2.9 3.9 6.3§ 
->6 ~zg/liter (1.5-45) (1.6-51) (1.8-58) (1.4-42) (1.7-49) (0.5-21) (0.7-28) (1.3-41) 
Troponin T 4.7§ 5.6§ 4.5[l 4.6§ 5.2§ 5.9¶ 4.2 4.9§ 
->0.20 ,ag/liter (1.04-23) (1.2-28) (0.98-22) (1.(10-22) (1.2-24) (0.94-45) (0.7-29) (1.02-24) 
Myosin light chains 5.0§ 4.8§ 5.5§ 5.0§ 6.4§ 6.0¶ 5.2¶ 4.3¶ 
>0.4 tsg/liter (i.1-26) (1.06-25) (1.2-29) (1.1-26) (1.4-33) (0.90-69) (0.87-38) (0.91-23) 
*Recurrent chest pain during 1st 48 h. tSupraventricular or ventricular tachycardia during the 1st 48 h. +p < 0.01. §p < 0.05. lip < 0.06. ¶p < 0.08. Data presented 
are odds ratio (95% confidence interval). Confidence intervals and p values are exact. CHF = congestive heart failure; other abbreviations a in Tables l to 3. 
rent chest pain; and occurrence of supraventricular o ventric- 
ular tachycardia, or both, during the 1st 48 h after admission. 
In addition to clinical conditions, CK-MB mass, troponin T 
and myosin light chains levels convey independent prognostic 
information. However, only knowledge of previous myocardial 
infarction; myocardial infarction or angina pectoris, or both, 
added independent prognostic information with regard to 
biochemical markers. The finding that hese sensitive biochem- 
ical markers do not add independent prognostic information 
with respect o ST-T wave abnormalities on admission or a 
transient ST-T wave shift on serial ECGs, or vice versa, points 
to the possibility that they reflect the same process in the 
myocardium. However, nondiagnostic ECG results are so 
common that the use of sensitive biochemical markers for 
diagnosis is advantageous (28). 
Minor myocardial injury and clinical outcome. The present 
investigation and other recent studies (3,11-14) imply that 
detection of minor myocardial injuries by sensitive biochemical 
markers is as important as diagnosing acute myocardial infarc- 
tion by other means. The parallel cardiac event curves during 
the entire follow-up period for patients with acute myocardial 
infarction and those with elevated CK-MB mass, troponin T or 
myosin light chain levels illustrate the similarity of these 
patients. One might herefore consider this group to be part of 
the spectrum of patients with non-Q wave myocardial infarc- 
tion, as proposed by earlier angiographic and clinical studies 
and because newer insight into the pathogenesis of the acute 
coronary syndromes has shown that minor myocardial cell 
necrosis occurs frequently in high risk patients (29,30). Most 
later cardiac events occurred in patients with unstable angina 
pectoris, and their identification could complement a risk 
stratification scheme for selection of patients for coronary 
angiography (27). However, future prospective studies must 
determine whether patients o identified will benefit from 
more aggressive medical treatment (e.g., thrombolytic, antico- 
agulant, antithrombotic agents) or invasive revascularization 
procedures, or both. 
Conclusions. Increased levels of serum CK-MB mass, tro- 
ponin T and myosin light chains all detect a subgroup of 
patients in whom an acute myocardial infarction has been 
ruled out but with a prognosis as grave as that of patients with 
a definite diagnosis of acute myocardial infarction. All three 
biochemical markers convey similar important independent 
prognostic information with regard to clinical findings and 
arrhythmias but add no additional prognostic information once 
the ECG ST-T wave changes are considered. 
We thank Morten Frydenberg, MSc, PhD, Department of Biostatistics, Aarhus 
University, Denmark, for performing the statistical analysis. 
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